Gliflozins: glucose-lowering and nonglycemic effects of new class of antidiabetic medications

The review summarizes the glucose-lowering and nonglycemic clinicaleffectsofthenew antidiabetic medications (gliflozins) that reduce renal reabsorption of glucose through inhibiting SGLT2 sodium-glucose cotransporter and induce glysosuria. Gliflozins can be used in combination with any oral glucoselowering agents and insulin. Treatment with SGLT2 inhibitors is associated with weight loss and a low risk of hypoglycemia though they increase the risk of urogenital infections.

Key words

Type 2 diabetes, SGLT2, gliflozins, dapagliflozin, empagliflozin, kanagliflozin.